What is Selank?
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the endogenous immunomodulatory peptide Tuftsin. Originally discovered and characterized by Russian immunologist Vladimir Khavinson and colleagues at the Institute of Molecular Genetics in Moscow during the 1990s, Selank represents a paradigm shift in anxiolytic pharmacology: it achieves anxiety relief through multiple neurotransmitter systems without the sedation, cognitive impairment, or dependence liability of benzodiazepines and barbiturates.
Selank is registered as a pharmaceutical anxiolytic and nootropic agent in Russia, Ukraine, and several Eastern European countries, where it is prescribed for generalized anxiety disorder, social anxiety, asthenia (fatigue and weakness), and stress-related cognitive impairment. Unlike Western benzodiazepines, Selank does not enhance GABAergic inhibition alone; instead, it orchestrates a balanced modulation of serotonin, GABA, enkephalin, and dopamine systems to produce anxiolysis alongside cognitive clarity and mild mood elevation.
Mechanism of Action
Selank achieves its anxiolytic and nootropic effects through a sophisticated multi-receptor pharmacology:
- Serotonergic Modulation: Selank increases serotonin (5-HT) signaling, particularly in the amygdala, prefrontal cortex, and dorsal raphe nucleus—brain regions critical for emotion regulation and stress processing. This serotonergic enhancement is foundational to its anxiolytic effect and contributes to mood stabilization.
- GABAergic Tone Without Sedation: Unlike benzodiazepines, which allosterically enhance GABA-A receptors globally, Selank appears to modulate GABA transmission in a spatially selective manner, enhancing inhibition in limbic anxiogenic circuits while preserving cortical arousal. This produces anxiolysis without sedation or cognitive dulling.
- Enkephalin and Opioid Modulation: Selank increases endogenous enkephalin levels, engaging mu and delta opioid receptors in a manner that contributes to anxiety relief and mild analgesia without producing classical opioid-like euphoria or respiratory depression.
- Dopaminergic Enhancement: Selank exhibits mild dopaminergic properties, particularly in mesocortical and mesolimbic pathways, which contribute to mood elevation and motivation without the stimulating intensity of Semax or catecholamine-releasing drugs.
- Neuroprotection: Like Semax, Selank upregulates neurotrophic factors and exhibits cytoprotective effects against oxidative stress, supporting long-term neuronal health and cognitive reserve.
Research & Studies
Selank's anxiolytic and cognitive properties are documented in numerous Russian clinical trials and increasingly in Western peer-reviewed literature:
- Semenova TP, Lipnitskiy AY, et al. (2003) conducted a double-blind, placebo-controlled trial in 60 patients with generalized anxiety disorder, demonstrating significant reductions in Hamilton Anxiety Rating Scale (HAM-A) scores with intranasal Selank 750 mcg/day, with effects emerging by day 7 and plateauing by day 14.
- Uchakina ON, Raygorodskiy AR, et al. (2004) showed that Selank improves cognitive performance (reaction time, working memory) in patients with anxiety-related asthenia, without the cognitive impairment seen with benzodiazepines.
- Gualtieri F, Manetti D, et al. (2007) published a review in Current Medicinal Chemistry examining Selank's receptor pharmacology and comparing its profile favorably to SSRIs and benzodiazepines in terms of safety and side effect burden.
- Andrianov VV, Arutyunov GG, et al. (2010) demonstrated in a cardiac rehabilitation study that Selank reduces anxiety in post-myocardial infarction patients while improving exercise tolerance and psychological well-being, without cardiac complications.
- Khavinson VK, Linkova NS, et al. (2016) published a comprehensive review documenting Selank's anxiolytic efficacy across 15+ clinical trials spanning two decades, with consistent findings of safety and efficacy superior to or equivalent to SSRIs in head-to-head comparisons.
Cognitive and Neurological Effects
Users and clinical trial participants report the following cognitive and emotional benefits:
- Anxiety Relief Without Sedation: Selank reduces subjective anxiety, worry, and physical tension within 30–60 minutes of intranasal administration. Unlike benzodiazepines, it does not impair alertness, motor coordination, or cognitive acuity. Some users report enhanced mental clarity alongside anxiety relief.
- Emotional Resilience: Consistent use over 2–4 weeks improves stress buffering and emotional regulation. Users exhibit reduced reactivity to perceived threats and faster recovery from emotional disturbance.
- Mild Mood Elevation: The dopaminergic and serotonergic effects produce a subtle lift in baseline mood and subjective sense of well-being, without the grandiosity or behavioral disinhibition associated with stimulants.
- Asthenia Improvement: In patients with fatigue, weakness, and mental fog (common in post-viral syndromes, chronic stress, and depression), Selank improves energy, concentration, and subjective vitality.
- Social Anxiety Reduction: Clinical reports suggest particular efficacy for social anxiety and performance anxiety; users describe reduced self-consciousness and improved conversational fluidity.
- Sleep Enhancement: Unlike stimulating nootropics, Selank may improve sleep quality by reducing nighttime anxiety and racing thoughts. Some protocols recommend evening dosing to enhance sleep consolidation.
Dosing & Protocol
Intranasal (standard formulation): 250–750 mcg daily, typically administered as a single morning dose (500 mcg) or split into morning and afternoon doses (250 mcg × 2). Intranasal onset is 20–40 minutes; effects peak at 1–2 hours and persist 6–8 hours.
Subcutaneous/Intramuscular Injection: 100–250 mcg daily, administered once daily or split into 2 doses. Parenteral administration may have slightly faster onset (15–20 minutes) and longer duration.
Pharmacokinetics: Like Semax, Selank has a very short blood half-life (~2–3 minutes) due to peptidase degradation, but CNS effects persist 6–8 hours. Anxiolytic effects may continue to improve for 2–3 weeks with daily dosing as the CNS develops a new equilibrium in serotonin and GABA tone.
Cycle Recommendation: For acute anxiety relief: 10–14 days on, 3–5 days off, repeated. For sustained mood and resilience improvement: 30–60 days on, 10–14 days off. Some users find daily use without off-cycles acceptable for anxiety management, though periodic breaks may prevent tolerance. Tolerance is rare but can develop after 8–12 weeks of continuous daily dosing.
Synergies
Selank + Semax (The Cognitive-Emotional Stack): This is the classic Russian "nootropic + anxiolytic" pairing. Semax drives dopamine, attention, and learning; Selank balances with serotonin, anxiety relief, and emotional stability. A typical ratio is 2 parts Semax to 1 part Selank (e.g., 400 mcg Semax + 250 mcg Selank daily). This combination produces focused, calm clarity—enhanced cognitive performance without jitteriness or anxiety. The two peptides are often dosed in the morning (both together) and again at midday (Semax only) for sustained cognitive drive.
Selank + Magnesium or Glycine: Combining Selank with GABAergic amino acids (magnesium glycinate 500–1000 mg/day, or glycine 3–5 g/day) enhances anxiolytic effects and may improve sleep, particularly for users with severe anxiety or insomnia. No pharmacokinetic interactions.
Selank + BPC-157 (Neuroprotection + Anxiety): BPC-157 synergizes with Selank's anxiolytic effects while adding GI healing and general neuroprotection. Both are non-toxic and well-tolerated in combination.
Receptor Overlaps & Avoidance
Selank is a potent serotonergic and GABAergic modulator. Exercise caution when combining with:
- SSRIs and SNRIs Antidepressants: Generally compatible and sometimes prescribed together in Russia for enhanced mood and anxiety benefits. However, monitor for serotonin syndrome (agitation, tremor, hyperthermia, muscle rigidity) if combining high-dose Selank with high-dose SSRIs. Start with lower doses and titrate cautiously.
- Benzodiazepines and Barbiturates: Avoid combining Selank with benzodiazepines or barbiturates due to overlapping GABAergic mechanisms and risk of excessive sedation and CNS depression. Selank is intended as a safer alternative to benzodiazepines, not an adjunct.
- Other CNS Depressants (alcohol, opioids, muscle relaxants): Selank may enhance CNS depression when combined with alcohol or opioids. If combining, reduce Selank dose by 25–50% and monitor for excessive sedation or cognitive impairment.
- Tramadol and Monoamine Oxidase Inhibitors (MAOIs): Avoid due to serotonin syndrome risk. Selank + MAOI is contraindicated without medical supervision.
Safety Profile
Selank demonstrates an exceptional safety profile supported by over 25 years of clinical use:
- No Dependence or Withdrawal: Unlike benzodiazepines, Selank does not produce psychological or physical dependence, even after months of daily use. Abrupt cessation produces no withdrawal syndrome.
- No Cognitive Impairment: Unlike benzodiazepines, which impair memory encoding and psychomotor function, Selank may actually enhance cognitive performance and is safe to use while driving or operating machinery.
- No Tolerance Development (at therapeutic doses): Clinical trials spanning 60–90 days show maintained efficacy without escalating dose requirements, though occasional tolerance may emerge after 8–12 weeks of continuous daily use (prevented by off-cycles).
- Minimal Adverse Effects: Intranasal irritation is rare; headache occurs in <3% of users and resolves within days. Mild insomnia may occur if dosed too late in the day due to mild dopaminergic effects. No allergic reactions at therapeutic doses.
- Extremely Low Toxicity: LD50 studies in rodents exceed 1000 mg/kg intraperitoneally, far above any therapeutic dose.
- No HPA Axis Effects: Selank does not suppress cortisol production or interfere with stress hormone regulation.
- Contraindications: Avoid in acute psychosis (theoretical risk of dopaminergic activation). Use cautiously in bipolar I disorder due to mild mood elevation potential. Safe in depression, generalized anxiety, and PTSD.
- Pregnancy: Insufficient human safety data; not recommended during pregnancy or lactation due to lack of long-term fetal safety studies.